Generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar
The main objective of this scale-up work was to increase access to early diagnosis and treatment (through trained, paid community health workers) in selected hotspots. This project is a scale-up of the TCE project (here).
- Drug & regimen: 3 consecutive rounds were administered 1 month apart of dihydroartemisinin–piperaquine (7 mg/kg -55 mg/kg orally) + single-dose primaquine (0.25mg/kg) through delivery at the malaria posts
- Concomitant interventions: Increased access to early diagnosis and treatment through community-based malaria posts, community engagement
- Exclusion criteria: Children younger than 6 months, individuals with a known allergy to the antimalarial drugs, women in the first trimester of pregnancy. Women in the second and third trimester of pregnancy, as well as breastfeeding mothers, were eligible for DP treatment but were excluded from the single dose of primaquine.
- Outcome measures:
- Change in village incidence measured from RDT confirmed cases at the community health post (malaria post)
- Change in prevalence, measured using highly sensitive qPCR approach (before and after MDA)
Allocation: Non- Randomized
Intervention model: Single-group
Masking: Non (open label)
Primary purpose: Prevention